289 related articles for article (PubMed ID: 25047832)
21. Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription.
Zhou M; Halanski MA; Radonovich MF; Kashanchi F; Peng J; Price DH; Brady JN
Mol Cell Biol; 2000 Jul; 20(14):5077-86. PubMed ID: 10866664
[TBL] [Abstract][Full Text] [Related]
22. Cyclin-dependent kinase inhibitor p16INK4A inhibits phosphorylation of RNA polymerase II by general transcription factor TFIIH.
Serizawa H
J Biol Chem; 1998 Mar; 273(10):5427-30. PubMed ID: 9488660
[TBL] [Abstract][Full Text] [Related]
23. TFIIH-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II.
Glover-Cutter K; Larochelle S; Erickson B; Zhang C; Shokat K; Fisher RP; Bentley DL
Mol Cell Biol; 2009 Oct; 29(20):5455-64. PubMed ID: 19667075
[TBL] [Abstract][Full Text] [Related]
24. Cdk7 mediates RPB1-driven mRNA synthesis in Toxoplasma gondii.
Deshmukh AS; Mitra P; Maruthi M
Sci Rep; 2016 Oct; 6():35288. PubMed ID: 27759017
[TBL] [Abstract][Full Text] [Related]
25. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
Chen R; Wierda WG; Chubb S; Hawtin RE; Fox JA; Keating MJ; Gandhi V; Plunkett W
Blood; 2009 May; 113(19):4637-45. PubMed ID: 19234140
[TBL] [Abstract][Full Text] [Related]
26. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
Whittaker SR; Walton MI; Garrett MD; Workman P
Cancer Res; 2004 Jan; 64(1):262-72. PubMed ID: 14729633
[TBL] [Abstract][Full Text] [Related]
27. Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine.
Paprskárová M; Krystof V; Jorda R; Dzubák P; Hajdúch M; Wesierska-Gadek J; Strnad M
J Cell Biochem; 2009 Jun; 107(3):428-37. PubMed ID: 19308936
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis.
Zhong L; Yang S; Jia Y; Lei K
J Cell Biochem; 2018 Dec; 119(12):9742-9751. PubMed ID: 30145799
[TBL] [Abstract][Full Text] [Related]
29. The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382.
Ljungman M; Paulsen MT
Mol Pharmacol; 2001 Oct; 60(4):785-9. PubMed ID: 11562441
[TBL] [Abstract][Full Text] [Related]
30. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
[TBL] [Abstract][Full Text] [Related]
31. The CDK7 inhibitor THZ1 alters RNA polymerase dynamics at the 5' and 3' ends of genes.
Sampathi S; Acharya P; Zhao Y; Wang J; Stengel KR; Liu Q; Savona MR; Hiebert SW
Nucleic Acids Res; 2019 May; 47(8):3921-3936. PubMed ID: 30805632
[TBL] [Abstract][Full Text] [Related]
32. HIV-1 Tat-associated RNA polymerase C-terminal domain kinase, CDK2, phosphorylates CDK7 and stimulates Tat-mediated transcription.
Nekhai S; Zhou M; Fernandez A; Lane WS; Lamb NJ; Brady J; Kumar A
Biochem J; 2002 Jun; 364(Pt 3):649-57. PubMed ID: 12049628
[TBL] [Abstract][Full Text] [Related]
33. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
[TBL] [Abstract][Full Text] [Related]
34. Induction of UGT1A1 and CYP2B6 by an antimitogenic factor in HepG2 cells is mediated through suppression of cyclin-dependent kinase 2 activity: cell cycle-dependent expression.
Sugatani J; Osabe M; Kurosawa M; Kitamura N; Ikari A; Miwa M
Drug Metab Dispos; 2010 Jan; 38(1):177-86. PubMed ID: 19797611
[TBL] [Abstract][Full Text] [Related]
35. Characterization of new highly selective pyrazolo[4,3-d]pyrimidine inhibitor of CDK7.
Kovalová M; Havlíček L; Djukic S; Škerlová J; Peřina M; Pospíšil T; Řezníčková E; Řezáčová P; Jorda R; Kryštof V
Biomed Pharmacother; 2023 May; 161():114492. PubMed ID: 36931035
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma.
Choi YJ; Kim DH; Yoon DH; Suh C; Choi CM; Lee JC; Hong JY; Rho JK
Sci Rep; 2019 May; 9(1):7193. PubMed ID: 31076643
[TBL] [Abstract][Full Text] [Related]
37. Comparative genomics of cyclin-dependent kinases suggest co-evolution of the RNAP II C-terminal domain and CTD-directed CDKs.
Guo Z; Stiller JW
BMC Genomics; 2004 Sep; 5():69. PubMed ID: 15380029
[TBL] [Abstract][Full Text] [Related]
38. Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors.
Kalan S; Amat R; Schachter MM; Kwiatkowski N; Abraham BJ; Liang Y; Zhang T; Olson CM; Larochelle S; Young RA; Gray NS; Fisher RP
Cell Rep; 2017 Oct; 21(2):467-481. PubMed ID: 29020632
[TBL] [Abstract][Full Text] [Related]
39. cdk-7 Is required for mRNA transcription and cell cycle progression in Caenorhabditis elegans embryos.
Wallenfang MR; Seydoux G
Proc Natl Acad Sci U S A; 2002 Apr; 99(8):5527-32. PubMed ID: 11960010
[TBL] [Abstract][Full Text] [Related]
40. Ibulocydine is a novel prodrug Cdk inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells.
Cho SJ; Kim YJ; Surh YJ; Kim BM; Lee SK
J Biol Chem; 2011 Jun; 286(22):19662-71. PubMed ID: 21478145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
